C D Blanke

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. doi request reprint Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer
    C D Blanke
    British Columbia Cancer Agency and University of British Columbia, BC, Canada
    Invest New Drugs 27:374-8. 2009
  2. doi request reprint Biomarkers in GIST: partly ready for prime-time use
    Charles D Blanke
    University of British Columbia and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 15:5603-5. 2009
  3. pmc S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach
    Charles D Blanke
    Division of Medical Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, BC
    Am J Clin Oncol 33:117-20. 2010
  4. doi request reprint Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors
    Charles D Blanke
    University of British Columbia and British Columbia Cancer Center, Vancouver, BC, Canada
    J Med Econ 13:681-90. 2010
  5. doi request reprint Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials
    Charles D Blanke
    University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 29:2781-6. 2011
  6. pmc KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice
    Charles D Blanke
    University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Oncologist 16:1061-8. 2011

Detail Information

Publications6

  1. doi request reprint Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer
    C D Blanke
    British Columbia Cancer Agency and University of British Columbia, BC, Canada
    Invest New Drugs 27:374-8. 2009
    ..To determine the safety and efficacy of weekly high-dose oral calcitriol and docetaxel, given to patients with non-resectable, incurable pancreatic cancer...
  2. doi request reprint Biomarkers in GIST: partly ready for prime-time use
    Charles D Blanke
    University of British Columbia and the British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Clin Cancer Res 15:5603-5. 2009
    ....
  3. pmc S9511: a Southwest Oncology Group phase II study of trimetrexate, 5-fluorouracil, and leucovorin in unresectable or metastatic adenocarcinoma of the stomach
    Charles D Blanke
    Division of Medical Oncology, University of British Columbia and British Columbia Cancer Agency, Vancouver, BC
    Am J Clin Oncol 33:117-20. 2010
    ..The primary objective of this trial was to evaluate the response rate for trimetrexate in conjunction with 5-FU and leucovorin (LV) (= TFL) in the treatment of advanced gastric cancer in a phase II, cooperative group setting...
  4. doi request reprint Cost effectiveness of tyrosine kinase inhibitor therapy in metastatic gastrointestinal stromal tumors
    Charles D Blanke
    University of British Columbia and British Columbia Cancer Center, Vancouver, BC, Canada
    J Med Econ 13:681-90. 2010
    ..Sunitinib, a multitargeted kinase inhibitor is effective against imatinib-resistant or intolerant GIST patients. Although the cost of TKI therapy in GIST is high, no other effective systemic treatment options exist...
  5. doi request reprint Impact of young age on treatment efficacy and safety in advanced colorectal cancer: a pooled analysis of patients from nine first-line phase III chemotherapy trials
    Charles D Blanke
    University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 29:2781-6. 2011
    ..We sought to determine whether young age is prognostic, or whether it influences efficacy/toxicity of chemotherapy, in patients with advanced disease...
  6. pmc KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice
    Charles D Blanke
    University of British Columbia and British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Oncologist 16:1061-8. 2011
    ..The overall goals are to highlight lessons learned regarding early disclosure of clinical trial results, as well as vetting and adoption of new scientific data, and to propose modifications for handling similar situations in the future...